Dendritic cells (DC) pulsed with triiodothyronine (T3) in the presence of tumor antigens induce a potent antitumor response: Role of T3 as adjuvant in DC-based câncer vaccines.

ALAMINO VA; GIGENA N; MONTESINOS, MM; DONADIO, AC; MILOTICH, S; MASINI-REPISO AM; RABINOVICH GA; PELLIZAS CG

Florianópolis

Congreso; XV Congreso Latinoamericano de Tiroides (LATS).; 2013

Sociedad Latinoamericana de Tiroides (LATS)

Background: We demonstrated that mice DC express thyroid hormone receptor β1 and that T3 stimulates DC maturation, IL-12 production and T cell allostimulatory capacity directing a T1-type response (FASEB J 2008,22:1032) involving Akt and NFkB activation signals (JBC 2010,285:9569). Moreover, T3 increased DC ability to stimulate cytotoxic antigen-specific responses and antigen cross-presentation (RAEM 2010,47:77). Objectives: 1) to evaluate apoptosis in T3-treated DC, 2) to analyze the migratory capacity of T3-stimulated DC, 3) to assess the capacity of T3-matured DC in the presence of tumor antigens to stimulate an antitumoral response in vivo. Methods: Mice bone marrow derived DC were pulsed with T3 (5nM) for 18 h. Apoptosis and DC migratory ability were analyzed by standard methodologies. For mice antitumor vaccination, B16-OVA melanoma model was used and immunizations with T3-pulsed DC in the presence of OVA were administered at 1, 3, 5 and 8 days after tumor cell inoculation. Tumor size was measured with vernier calipers and mice survival registered. Lymphocyte T linage was determined in tumor infiltrating cells and IFN-γ measured in esplenocytes. P